SMS2 increased the expression of lipid-raft-associated FLOT2 by upregulating SM, which subsequently activated the NF-κB signaling pathway and promoted cell stemness of breast cancer cells, thus increasing the drug resistance toward ADR. Here, SGMS2 is linked to breast carcinoma.